-
What is the largest increase in Hengrui, Shanghai Pharmaceuticals, CSPC, and Yangtze River's impact on the top 20 global pharmaceutical companies?
Time of Update: 2021-08-16
Generally speaking, there are two paths: after the innovative drug is listed in the mainstream market, it becomes a blockbuster with annual revenue of over US$1 billion; or it "subverts" Hengrui's past development genes and completes a major acquisition .
-
U.S. biosimilar drugs may welcome ten years of continuous growth
Time of Update: 2021-08-16
. "Ronny Gal, an analyst at Bernstein in the United States, said in a quarterly study on the performance and prospects of biosimilars, "Although it may not be obvious on the surface, biosimilars have always been the main force in easing drug prices .
-
Qianjin Pharmaceutical Co., Ltd. Valsartan tablets obtained drug registration certificate and regarded as over-evaluated
Time of Update: 2021-08-16
On the 24th, Qianjin Pharmaceutical announced that its subsidiary Qianjin Xiangjiang Pharmaceutical received the "Drug Registration Certificate" for valsartan tablets approved by the State Food and Drug Administration.
Valsartan tablets are an angiotensin II receptor blocker developed by Novartis, Switzerland, and are mainly used for mild to moderate essential hypertension .
-
Reached the main clinical endpoint!
Time of Update: 2021-08-16
Note: The original text has been deletedReference materials:[1] Jun Shengtai will present the results of the Phase II clinical trial of HTD1801 in the treatment of primary sclerosing cholangitis.
-
The world's first 14-valent HPV vaccine! Shenzhou cell SCT1000 enters the clinic
Time of Update: 2021-08-16
Recently, Shenzhou Cell announced that its self-developed 14-valent HPV vaccine SCT1000 has entered clinical phase I/II studies and completed the enrollment of all 80 subjects .
It is worth noting that this is the world's first 14-valent HPV vaccine to enter the clinical research phase .
-
In the first half of the year, 36 pharmaceutical companies got together and listed on the market, and the financing of innovative drugs ushered in a climax?
Time of Update: 2021-08-16
At the same time, the total IPO funds raised by 22 medical device companies in the two markets exceeded 24 billion yuan in the first half of the year .
-
A giant pharmacy store will break 10,000
Time of Update: 2021-08-16
In 2020, the common people's pharmacy told the media that in the next three years, the company will maintain a growth rate of about 2,000 new stores each year, including directly-operated stores, franchised stores, and mergers and acquisitions stores .
-
The Gains and Losses of Separation of Medicine from Japan
Time of Update: 2021-08-16
Therefore, the stagnation of the prescription drug market in Japan after 2015 is due to the replacement strategy of generic drugs, which means that as long as the payment policy is adjusted at the drug sales terminal, the total drug cost can be effectively controlled, which was promoted by the previous large-scale redemption policy.
-
The second half of 2021: medical representatives are difficult
Time of Update: 2021-08-16
Similar to the impact of national centralized procurement, for medical representatives, as local supplementary products are gradually removed from medical insurance, they will also face the problem of transformation or job transfer .
-
New indication for AstraZeneca dovalizumab is about to be approved in China
Time of Update: 2021-08-16
According to the official website of China's National Food and Drug Administration, AstraZeneca's blockbuster PD-L1 inhibitor durvalumab injection (durvalumab, trade name: Imfinzi) has a new indication for the market.
-
154 million!
Time of Update: 2021-08-16
On February 5 of the same year, Yixintang issued an announcement stating that its wholly-owned subsidiary, Shanxi Yixintang, planned to acquire 29 store assets held by Shanxi Baixing Pharmaceutical Chain Co.
-
Beida Pharmaceuticals BPI-23314 drug clinical trial application accepted
Time of Update: 2021-08-16
On the 29th, Betta Pharmaceuticals announced that it received the "Notice of Acceptance" issued by the NMPA, and the company declared BPI-23314 tablets for the treatment of malignant hematological tumors (including but not limited to myelofibrosis and other myeloproliferative tumors and myelodysplastic syndromes.
-
Five people detained for selling aphrodisiac drugs in pharmacies
Time of Update: 2021-08-16
It was identified that the 9 types of sexual health products involved in the case contained toxic and harmful non-food ingredients "sildenafil" or "tadalafil" and other ingredients that are expressly prohibited from being added, and none of them were produced by the relevant company or applied the approval number of the company.
-
Inventory of new drugs approved and accepted by NMPA in the first half of 2021
Time of Update: 2021-08-16
. The approval of vedicitumumab broke the situation that there is no original domestic new drug in the ADC drug field, and filled the gap in the treatment of patients with HER2 overexpression gastric cancer.
The listing of this variety provides a new treatment option for adult patients with non-small cell lung cancer (NSCLC) .
-
Hutchison Medicine initiates phase I clinical trials of a new ERK inhibitor HMPL-295 in China
Time of Update: 2021-08-16
After the initial dose escalation phase, an additional 10 to 15 patients will be included in the study and receive the recommended dose of phase II clinical study to further evaluate the safety and preliminary efficacy of HMPL-295 .
-
FDA releases Biogen Alzheimer's disease new drug review memorandum
Time of Update: 2021-08-16
Peter Stein, director of the Office of New Drugs, and the memorandum signed by Dr.
According to the data, CDER Director Patrizia Cavazzoni and Director of the Office of New Drugs Peter Stein both agreed with the accelerated approval proposed by Billy Dunn, head of FDA neuroscience, while the staff of the FDA Office of Biostatistics believed that approval was unnecessary .
-
After Aducanumab was approved, the development of new drugs for Alzheimer's disease is surging
Time of Update: 2021-08-16
Text | Pickup BayOn June 7, the FDA accelerated the approval of Biogen/Eisai’s Aβ (amyloid β) antibody Aduhelm (aducanumab) for the treatment of Alzheimer’s disease (AD) patients with a biological product license (BLA) based on the biomarker surrogate endpoint.
-
Lansoprazole, ranitidine...another alliance starts drug procurement and reporting work
Time of Update: 2021-08-16
According to MRCLUB, on July 10, the Henan Provincial Medical Insurance Bureau announced the Henan-China Alliance’s "Notice on Filling in the Pre-purchasing Quantity of Drugs Procured in Centralized Purchases".
-
Tonghua Dongbao: Dongbao Zixing three-target inhibitor product obtained clinical approval
Time of Update: 2021-08-16
On June 28, Tonghua Dongbao announced that its three-target inhibitor product (THDBH101 capsule/WXSHC071 capsule) has been approved for clinical application.
As of the date of this announcement, the company has invested approximately RMB 25.
27 million in research and development expenses in this project .
-
These "special" pharmacies cut prices by more than 50%
Time of Update: 2021-08-16
You can buy medicines that are reimbursed by medical insurance at a special outpatient pharmacy nearby .
In addition, 61 designated hospitals in Liuyang can also handle special outpatient services, realizing "dual-channel" purchase of medicines for outpatients of special diseases .
